Evolent Health Q4 2019 Earnings Report
Key Takeaways
Evolent Health reported a 22.5% increase in GAAP revenue, reaching $236.5 million for the fourth quarter of 2019. The company's net loss attributable to common shareholders was $(198.1) million, which included a non-cash goodwill impairment of $199.8 million. Adjusted EBITDA stood at $8.2 million, and the company had approximately 3.7 million lives on its platform.
GAAP revenue increased by 22.5% to $236.5 million.
Net loss attributable to common shareholders was $(198.1) million, impacted by a non-cash goodwill impairment.
Adjusted EBITDA reached $8.2 million.
Approximately 3.7 million lives were on the platform.
Evolent Health
Evolent Health
Evolent Health Revenue by Segment
Forward Guidance
For the full year 2020, revenue is expected to be in the range of approximately $935.0 million to $985.0 million. Adjusted EBITDA for the full year is expected to be $24.0 million to $32.0 million. For the three months ended March 31, 2020, revenue is expected to be in the range of approximately $233.5 million to $245.5 million. Adjusted EBITDA is expected to be in the range of approximately $2.0 million to $5.0 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income